Navigation Links
Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Date:3/3/2009

RICHMOND, Calif., March 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at two investor conferences during the month of March.

  • Barclays Capital Global Healthcare Conference at 3:45 pm ET, on Tuesday, March 10, 2009
  • Cowen and Company 29th Annual Health Care Conference at 8:00 am ET, on Wednesday, March 18, 2009

The presentations will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
2. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
3. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
4. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
7. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
8. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
9. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... According to a new ... Product (Wheelchair, Scooters, Medical Beds, Bathroom Safety, Mechanical, ... Wound), Accessories (Lifting, Transfer) & by End User ... MarketsandMarkets, the patient handling equipment market is expected ... a CAGR of 10.5% during the forecast period ...
(Date:5/23/2016)... YORK , May 23, 2016 ... Spectrometry Market Size, Share, Development, Growth and Demand ... (Hybrid, Single and Other), by Application (Drug Discovery ... by End Users (Pharmaceuticals, Life Science and Biotechnology, ... by P&S Market Research, the global mass ...
(Date:5/23/2016)... , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International Conference of ... under the distinguished patronage and presence of Sheikh Nahyan bin ... conference focused in Precision Medicine, which helps provide personalized medicine ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... To better understand the ... research award to examine gender differences in lung cancer. Today, the Lung Association announced ... Lung Cancer in Women Award, funded by the American Lung Association’s LUNG FORCE initiative, ...
(Date:5/24/2016)... ... , ... Jericho Project has named LaToya Williams-Belfort to the position of Chief ... and communications for the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the ... at its roots. , “LaToya Williams-Belfort is joining Jericho at an exciting time ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The project ... services into a single site. , The new 2 story building houses the ...
(Date:5/24/2016)... ... 24, 2016 , ... Regenerative Medicine is being transformed by ongoing research and ... protocols and patient results as have been achieved with Okyanos Cell Therapy ... of care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Boyd Industries, ... Concealed Delivery Unit® (CDU), a groundbreaking new product for pediatric dentistry , at ... Dentistry in San Antonio, TX May 26-29. The Concealed Delivery Unit keeps dental hand ...
Breaking Medicine News(10 mins):